Genome-wide screening of aberrant DNA methylation which associated with gene expression in mouse skin cancers

Molecular Carcinogenesis

Volumn 54, Issue 3, 2015, Pages 178-188

  Fujiwara, Kyoko ^a   Ghosh, Srimoyee ^b   Liang, Ping ^c   Morien, Evan ^d   Soma, Masayoshi ^a   Nagase, Hiroki ^a,e  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NORTH EASTERN HILL UNIVERSITY   (India)

^c BROCK UNIVERSITY   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CHIBA CANCER CENTER   (Japan)

Author keywords

DNA methylation; Epigenetics; Mouse model; Squamous cell carcinoma

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INTRON; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SKIN CANCER; SKIN TUMOR SPECIFIC DIFFERENTIALLY METHYLATED REGION; SQUAMOUS CELL CARCINOMA CELL LINE; TFAP2E GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; C57BL MOUSE; CELL TRANSFORMATION; CHEMICALLY INDUCED; GENETIC EPIGENESIS; GENETICS; PAPILLOMA; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

MUS;

7,12 DIMETHYLBENZ[A]ANTHRACENE; AZACITIDINE; ENZYME INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; TFAP2E PROTEIN, HUMAN; TRANSCRIPTION FACTOR AP 2;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; AZACITIDINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED C57BL; PAPILLOMA; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TRANSCRIPTION FACTOR AP-2;

EID: 84926078424     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22085     Document Type: Article

References (34)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
2. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12:599-612.
3. Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011; 2:627-637.
4. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301:89-92.
5. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117:2713-2722.
6. Shao C, Sun W, Tan M, et al. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. Clin Cancer Res 2011; 17:4320-4330.
7. Russo V, Martienssen R, Riggs A. Epigenetic mechanisms of gene regulation. Plainview. New York: Cold Spring Harbor Laboratory Press; 1996.
8. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692.
9. Campan M, Moffitt M, Houshdaran S, et al. Genome-scale screen for DNA methylation-based detection markers for ovarian cancer. PLoS ONE 2011; 6:e28141.
10. Fackler MJ, Umbricht CB, Williams D, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 2011; 71:6195-6207.
11. Poage GM, Houseman EA, Christensen BC, et al. Global hypomethylation identifies Loci targeted for hypermethylation in head and neck cancer. Clin Cancer Res 2011; 17:3579-3589.
12. Shinojima Y, Terui T, Hara H, et al. Identification and analysis of an early diagnostic marker for malignant melanoma: ZAR1 intra-genic differential methylation. J Dermatol Sci 2010; 59:98-106.
13. Watanabe T, Yachi K, Ohta T, et al. Aberrant hypermethylation of non-promoter zygote arrest 1 (ZAR1) in human brain tumors. Neurol Med Chir (Tokyo) 2010; 50:1062-1069.
14. Watanabe T, Yachi K, Ohta T, et al. Non-promoter hypermethylation of zygote arrest 1 (ZAR1) in human brain tumors. Brain Tumor Pathol 2011; 28:199-202.
15. Wilkey JF, Buchberger G, Saucier K, et al. Cyclin D1 overexpression increases susceptibility to 4-nitroquinoline-1-oxide-induced dysplasia and neoplasia in murine squamous oral epithelium. Mol Carcinog 2009; 48:853-861.
16. Saab R, Rodriguez-Galindo C, Matmati K, et al. p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor. Cancer Res 2009; 69:440-448.
17. Nishijo K, Chen QR, Zhang L, et al. Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 2009; 69:2902-2911.
18. Zheng H, Ying H, Yan H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008; 455:1129-1133.
19. Zhang D, Hirota T, Marumoto T, et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 2004; 23:8720-8730.
20. Liang P, Song F, Ghosh S, et al. Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development. BMC Genomics 2011; 12:231.
21. Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18:1427-1431.
22. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004; 64:5527-5534.
23. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38:1378-1385.
24. Han H, Cortez CC, Yang X, Nichols PW, Jones PA, Liang G. DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. Hum Mol Genet 2011; 20:4299-4310.
25. Ebert MP, Tanzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012; 366:44-53.
26. Payne SR, Serth J, Schostak M, et al. DNA methylation biomarkers of prostate cancer: Confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection. Prostate 2009; 69:1257-1269.
27. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005; 6:246.
28. Wang HV, Vaupel K, Buettner R, Bosserhoff AK, Moser M. Identification and embryonic expression of a new AP-2 transcription factor, AP-2 epsilon. Dev Dyn 2004; 231:128-135.
29. Orso F, Penna E, Cimino D, et al. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J 2008; 22:2702-2714.
30. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997; 15:78-82.
31. Wang D, Shin TH, Kudlow JE. Transcription factor AP-2 controls transcription of the human transforming growth factor-alpha gene. J Biol Chem 1997; 272:14244-14250.
32. Kaufman CK, Sinha S, Bolotin D, Fan J, Fuchs E. Dissection of a complex enhancer element: Maintenance of keratinocyte specificity but loss of differentiation specificity. Mol Cell Biol 2002; 22:4293-4308.
33. Wang X, Bolotin D, Chu DH, Polak L, Williams T, Fuchs E. AP-2alpha: A regulator of EGF receptor signaling and proliferation in skin epidermis. J Cell Biol 2006; 172:409-421.
34. Gaubatz S, Imhof A, Dosch R, et al. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J 1995; 14:1508-1519.